Skip to main content
SpringerLink
Log in

The efficacy of rituximab in the treatment of refractory nephrotic syndrome: a meta-analysis

  • Nephrology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objective

The evidence from epidemiological research on whether the efficacy of rituximab in treatment of refractory nephrotic syndrome (NS) is better than other agents is inconsistent. This meta-analysis aimed to assess the efficacy of rituximab in the treatment of NS compared with other immunosuppressive agents.

Methods

Relevant literatures were identified and evaluated for quality before October 2019 through multiple search strategies on PubMed and EMBASE. Statistical evidence of the symmetry of the funnel plot obtained from Begg’s test was indicated by Egger’s linear regression and a sensitivity analysis identified heterogeneity. A fixed- or a random-effects model was applied to calculate the pooled SMDs and RRs.

Results

A total of 12 studies, involving 383 patients and 354 controls, were included. Compared with other agents, rituximab significantly improved complete remission both in children and adults [Overall: RR = 1.313, 95% CI = 1.170–1.475, P < 0.001; Adult: RR = 1.359, 95% CI = 1.053–1.753, P = 0.019 Children: RR = 1.354, 95% CI = 1.072–1.709, P < 0.001], and dramatically decreased the relapse rate in children [Overall: RR = 0.349, 95% CI = 0.166–0.732, P < 0.001; Children: RR = 0.286, 95% CI = 0.176–0.463, P < 0.001].

Conclusions

Rituximab might be a promising treatment for refractory NS. Compared with other agents, rituximab significantly improves the complete remission and decreased the relapse rate. However, to confirm the efficacy of rituximab in the treatment of refractory NS, more high-quality, large sample, and multicenter randomized controlled trials are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Crew RJ, Radhakrishnan J, Appel G (2004) Complications of the nephrotic syndrome and their treatment. Clin Nephrol 62(4):245–259

    Article  CAS  PubMed  Google Scholar 

  2. Basu B, Mahapatra TK, Mondal N (2015) Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome. Pediatrics 136(1):e132–e139. https://doi.org/10.1542/peds.2015-0486

    Article  PubMed  Google Scholar 

  3. Lombel RM, Gipson DS, Hodson EM (2013) Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 28(3):415–426. https://doi.org/10.1007/s00467-012-2310-x

    Article  PubMed  Google Scholar 

  4. Sinha A, Bagga A (2013) Rituximab therapy in nephrotic syndrome: implications for patients’ management. Nat Rev Nephrol 9(3):154–169. https://doi.org/10.1038/nrneph.2012.289

    Article  CAS  PubMed  Google Scholar 

  5. Larkins N, Kim S, Craig J, Hodson E (2016) Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch Dis Child 101(4):404–408. https://doi.org/10.1136/archdischild-2015-308924

    Article  PubMed  Google Scholar 

  6. Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L et al (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27(6):1811–1822. https://doi.org/10.1681/ASN.2015050523

    Article  CAS  PubMed  Google Scholar 

  7. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guerin V, Lapillonne H et al (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood—follow-up after CD19 recovery. Nephrol Dial Transplant 27(3):1083–1089. https://doi.org/10.1093/ndt/gfr405

    Article  CAS  PubMed  Google Scholar 

  8. Jayne D (2010) Role of rituximab therapy in glomerulonephritis. J Am Soc Nephrol 21(1):14–17. https://doi.org/10.1681/ASN.2008070786

    Article  CAS  PubMed  Google Scholar 

  9. Benz K, Dotsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19(7):794–797. https://doi.org/10.1007/s00467-004-1434-z

    Article  PubMed  Google Scholar 

  10. Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GM (2016) Anti-CD20 antibodies for idiopathic nephrotic syndrome in children. Clin J Am Soc Nephrol 11(4):710–720. https://doi.org/10.2215/CJN.08500815

    Article  CAS  PubMed  Google Scholar 

  11. Cravedi P, Sghirlanzoni MC, Marasa M, Salerno A, Remuzzi G, Ruggenenti P (2011) Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 33(5):461–468. https://doi.org/10.1159/000327611

    Article  CAS  PubMed  Google Scholar 

  12. Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D (2016) Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome. Pediatr Nephrol 31(4):589–594. https://doi.org/10.1007/s00467-015-3245-9

    Article  PubMed  Google Scholar 

  13. Zhao Z, Liao G, Li Y, Zhou S, Zou H (2015) The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis. Sci Rep 5:8219. https://doi.org/10.1038/srep08219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Solomon N, Lalayiannis AD (2019) Rituximab is more effective than tacrolimus in steroid-dependent nephrotic syndrome. Arch Dis Child Educ Pract Ed 104(5):279–280. https://doi.org/10.1136/archdischild-2018-316537

    Article  PubMed  Google Scholar 

  15. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M et al (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23(6):1117–1124. https://doi.org/10.1681/ASN.2011080775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L et al (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6(6):1308–1315. https://doi.org/10.2215/CJN.09421010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M et al (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled tTrial. J Am Soc Nephrol 26(9):2259–2266. https://doi.org/10.1681/ASN.2014080799

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. DaSilva I, Huerta A, Quintana L, Redondo B, Iglesias E, Draibe J et al (2017) Rituximab for steroid-dependent or frequently relapsing idiopathic nephrotic syndrome in adults: a retrospective multicenter study in Spain. BioDrugs 31(3):239–249. https://doi.org/10.1007/s40259-017-0221-x

    Article  CAS  PubMed  Google Scholar 

  19. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K et al (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384(9950):1273–1281. https://doi.org/10.1016/S0140-6736(14)60541-9

    Article  CAS  PubMed  Google Scholar 

  20. Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L et al (2017) Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 28(1):348–358. https://doi.org/10.1681/ASN.2016040449

    Article  CAS  PubMed  Google Scholar 

  21. van den Brand J, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B et al (2017) Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol 28(9):2729–2737. https://doi.org/10.1681/ASN.2016091022

    Article  PubMed  PubMed Central  Google Scholar 

  22. Sinha A, Bagga A, Gulati A, Hari P (2012) Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol 27(2):235–241. https://doi.org/10.1007/s00467-011-1997-4

    Article  PubMed  Google Scholar 

  23. Iorember F, Aviles D, Kallash M, Bamgbola O (2018) Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome. Pediatr Nephrol 33(2):261–267. https://doi.org/10.1007/s00467-017-3789-y

    Article  PubMed  Google Scholar 

  24. Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS et al (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172(8):757–764. https://doi.org/10.1001/jamapediatrics.2018.1323

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ahn YH, Kim SH, Han KH, Cho HY, Shin JI, Cho MH, Park YS, Kim SY, Lee SJ, Cheong HI, Ha I-S (2014) Selected abstracts from the 34th Annual Spring Meeting of the Korean Society of Nephrology 2014. Kidney Res Clin Pract 33:A1–A2

    Article  Google Scholar 

  26. Nielsen C, Laustrup H, Voss A, Junker P, Husby S, Lillevang ST (2004) A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients. Lupus 13(7):510–516

    Article  CAS  PubMed  Google Scholar 

  27. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F et al (2015) The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 8(1):2–10. https://doi.org/10.1111/jebm.12141

    Article  PubMed  Google Scholar 

  28. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

    Article  PubMed  PubMed Central  Google Scholar 

  29. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. https://doi.org/10.1002/sim.1186

    Article  PubMed  Google Scholar 

  30. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S et al (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5(12):2207–2212. https://doi.org/10.2215/CJN.03470410

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Tellier S, Brochard K, Garnier A, Bandin F, Llanas B, Guigonis V et al (2013) Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol 28(6):911–918. https://doi.org/10.1007/s00467-012-2406-3

    Article  PubMed  Google Scholar 

  32. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M et al (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24(7):1321–1328. https://doi.org/10.1007/s00467-009-1191-0

    Article  PubMed  Google Scholar 

  33. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y et al (2010) Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 25(3):539–544. https://doi.org/10.1007/s00467-009-1377-5

    Article  PubMed  Google Scholar 

  34. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G (2007) Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2(5):932–937. https://doi.org/10.2215/CJN.01180307

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Science Foundation of Anhui Medical University (2018xkj028). Refinement and implementation of the study were supported by The Second Affiliated Hospital of Anhui Medical University.

Author information

Authors and Affiliations

  1. Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, 230601, Anhui, China

    Jian-Ping Xiao, Ju Wang, Liang Yuan & De-Guang Wang

Authors
  1. Jian-Ping Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ju Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liang Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. De-Guang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jian-Ping Xiao or De-Guang Wang.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOC 32 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiao, JP., Wang, J., Yuan, L. et al. The efficacy of rituximab in the treatment of refractory nephrotic syndrome: a meta-analysis. Int Urol Nephrol 52, 1093–1101 (2020). https://doi.org/10.1007/s11255-020-02460-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-020-02460-8

Keywords

Search

Navigation